We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agenus' (AGEN) Q1 Loss Wider than Expected, Shares Down
Read MoreHide Full Article
Agenus Inc. (AGEN - Free Report) reported first-quarter 2018 adjusted loss of 42 cents per share (excluding loss on early extinguishment of debt of 11 cents per share), wider than both the Zacks Consensus Estimate of a loss of 28 cents and the year-ago loss of 18 cents. The higher net loss was due to several one-time items as well as non-cash charges.
The company did not generate any revenues in the quarter. The Zacks Consensus Estimate was $16 million. However, the company reported revenues of $27 million in the prior-year period.
Shares of the company fell about 9.8% following the earnings release. So far this year, shares of Agenus have gained 1.8% as against the industry’s decline of 11.9%.
Quarterly Highlights
Agenus’ first-quarter research and development (R&D) expenses declined 9.8% to $29.4 million. General and administrative expenses decreased by 8.1% to $10.7 million.
Pipeline Update
Agenus is progressing well with various pipeline candidates. During the quarter under review, the company launched combination trials of CTLA-4 antibody, AGEN1884 and PD-1 targeting antibody AGEN2034 including trials in second line cervical cancer.
The company has shifted its strategy for first approval from first line non-small cell lung cancerto second line cervical cancer. The reasons for the strategy shift includes increasingly crowded lung cancer opportunities and Merck’s (MRK - Free Report) recent data with Keytruda in combination with chemotherapy in first-line non-small cell lung cancer, which has set the bar higher for any future approvals.
The company remainson track to file six investigational new drugs (INDs) in 2018 and an additional two INDs in the first half of 2019. Amongst that, is the company’s next gen CTLA-4, designed to deplete cancer-prone Tregs and improve T-cell priming.
Ligand’s earnings per share estimates have moved up from $4.24 to $4.43 for 2018 over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 24.88%. The company’s shares have rallied 15% year to date.
Protagonist’s loss estimates narrowed from $1.30 to 66 cents for 2018 and from $1.99 to $1.26 for 2019, over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 24.95%.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Agenus' (AGEN) Q1 Loss Wider than Expected, Shares Down
Agenus Inc. (AGEN - Free Report) reported first-quarter 2018 adjusted loss of 42 cents per share (excluding loss on early extinguishment of debt of 11 cents per share), wider than both the Zacks Consensus Estimate of a loss of 28 cents and the year-ago loss of 18 cents. The higher net loss was due to several one-time items as well as non-cash charges.
The company did not generate any revenues in the quarter. The Zacks Consensus Estimate was $16 million. However, the company reported revenues of $27 million in the prior-year period.
Shares of the company fell about 9.8% following the earnings release. So far this year, shares of Agenus have gained 1.8% as against the industry’s decline of 11.9%.
Quarterly Highlights
Agenus’ first-quarter research and development (R&D) expenses declined 9.8% to $29.4 million. General and administrative expenses decreased by 8.1% to $10.7 million.
Pipeline Update
Agenus is progressing well with various pipeline candidates. During the quarter under review, the company launched combination trials of CTLA-4 antibody, AGEN1884 and PD-1 targeting antibody AGEN2034 including trials in second line cervical cancer.
The company has shifted its strategy for first approval from first line non-small cell lung cancerto second line cervical cancer. The reasons for the strategy shift includes increasingly crowded lung cancer opportunities and Merck’s (MRK - Free Report) recent data with Keytruda in combination with chemotherapy in first-line non-small cell lung cancer, which has set the bar higher for any future approvals.
The company remainson track to file six investigational new drugs (INDs) in 2018 and an additional two INDs in the first half of 2019. Amongst that, is the company’s next gen CTLA-4, designed to deplete cancer-prone Tregs and improve T-cell priming.
Zacks Rank & Stocks to Consider
Agenus has a Zacks Rank #3 (Hold).
A few better-ranked stocks from the same space worth considering are Ligand Pharmaceuticals (LGND - Free Report) and Protagonist Therapeutics (PTGX - Free Report) both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Ligand’s earnings per share estimates have moved up from $4.24 to $4.43 for 2018 over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 24.88%. The company’s shares have rallied 15% year to date.
Protagonist’s loss estimates narrowed from $1.30 to 66 cents for 2018 and from $1.99 to $1.26 for 2019, over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 24.95%.
Agenus Inc. Price, Consensus and EPS Surprise
Agenus Inc. Price, Consensus and EPS Surprise | Agenus Inc. Quote
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>